Disintegration time testing in artificial intestinal fluid is a core pharmacopoeial performance test used to verify that enteric-coated and delayed-release solid oral dosage forms break down completely under conditions that simulate the small intestine. Conducted in a pH 6.8 pancreatin-containing medium at 37°C, the test confirms both gastric resistance and intestinal release behavior in accordance with ChP, USP, and EP requirements. This article explains the test principles, sample types, procedures, acceptance criteria, and practical applications for pharmaceutical quality control laboratories.
Technical Overview
The disintegration time test in artificial intestinal fluid is a compendial quality control method that evaluates whether solid oral dosage forms—most commonly enteric-coated and delayed-release products—can disintegrate completely in a medium that reproduces the pH and enzymatic environment of the upper small intestine. Artificial intestinal fluid is defined as a pH 6.8 phosphate buffer containing pancreatin, which supplies amylase, protease, and lipase activity comparable to physiological intestinal secretions.
For enteric-coated dosage forms, the test is typically performed as a two-stage procedure. In the first stage, the dosage units are exposed to dilute hydrochloric acid to demonstrate resistance to gastric conditions. In the second stage, the same units are transferred to artificial intestinal fluid or pH 6.8 phosphate buffer to confirm that the coating dissolves and the dosage form disintegrates at the intended intestinal site. The method is governed by Chinese Pharmacopoeia General Chapter 0921 (Disintegration Test), USP General Chapter <701>, and EP Section 2.9.1.
Disintegration is judged complete when no palpable firm core remains and any residue consists only of insoluble fragments of the coating or capsule shell that are soft and mucoid in character. Because disintegration is a prerequisite for drug dissolution and absorption, this test is a fundamental in vitro indicator of in vivo performance for delayed-release products.
- Medium: artificial intestinal fluid (pH 6.8 phosphate buffer with pancreatin, typically 10 g per liter)
- Temperature: maintained at 37 ± 1°C throughout the test
- Basket stroke frequency: 30–32 cycles per minute
- Standard buffer-stage limit for enteric-coated tablets and capsules: complete disintegration within 60 minutes
- Apparatus: basket-rack assembly holding six dosage units per run
Testing Samples
Enteric-Coated Tablets
Enteric-coated tablets are film-coated with pH-sensitive polymers such as methacrylic acid copolymers, cellulose acetate phthalate, or hypromellose phthalate. These polymers remain intact in acidic gastric fluid but ionize and dissolve above pH 5.5–6.0. Both single-unit enteric tablets and enteric film-coated cores of compressed tablets are evaluated using the two-stage disintegration procedure.
Enteric-Coated Capsules
This category includes hard gelatin capsules that have been sealed and spray-coated with enteric polymers, as well as soft capsules whose shells incorporate enteric materials. Capsules may also be filled with enteric-coated pellets or granules, in which case the test verifies both the integrity of the outer shell and the release behavior of the multiparticulate fill in intestinal medium.
Delayed-Release Pellets, Granules, and Minitablets
Multiparticulate systems coated with enteric polymers are frequently tested in artificial intestinal fluid, either as an intermediate product during manufacture or as the final dosage form. The test confirms that the coating process achieves uniform protection in acid and rapid disintegration in intestinal pH, and it is often used during coating weight-gain optimization studies.
Colon-Targeted and Site-Specific Delivery Systems
For dosage forms designed to release drug in the distal intestine or colon, disintegration testing may extend the buffer stage or use successive media—for example, acid followed by pH 6.8 phosphate buffer followed by pH 7.8 phosphate buffer—as specified in the individual monograph or development protocol. Systems based on enzymatically degradable polymers or polysaccharides are particularly relevant to pancreatin-containing artificial intestinal fluid.
Testing Items
The disintegration time test in artificial intestinal fluid comprises several discrete evaluations that together characterize the release behavior of delayed-release dosage forms:
- Acid-stage resistance: exposure of six units to dilute hydrochloric acid (9 in 1000, approximately 0.1 mol/L) at 37°C for 2 hours, with no unit allowed to disintegrate, crack, or soften
- Buffer-stage disintegration time: complete disintegration of all units in artificial intestinal fluid within the specified limit, generally 60 minutes for enteric-coated tablets and capsules
- Medium verification: confirmation of medium pH (6.8 ± tolerance), fresh preparation and adequate enzymatic activity of pancreatin, and sufficient medium volume (approximately 1 liter per vessel)
- Instrument parameters: bath temperature of 37 ± 1°C, basket oscillation of 30–32 strokes per minute, and vertical travel of approximately 55 ± 2 mm
- Endpoint assessment: visual and tactile examination of residues to confirm the absence of a firm core and to qualify any remaining fragments as soft, mucoid, insoluble coating or shell debris
- Retest evaluation: repeat testing of six additional units when no more than one of the initial six units fails
Testing Methods
Preparation of Artificial Intestinal Fluid
Dissolve 6.8 g of potassium dihydrogen phosphate in 500 mL of purified water, adjust the pH to 6.8 with 0.1 mol/L sodium hydroxide solution, add 10 g of pancreatin, and dilute with water to 1000 mL. The medium should be freshly prepared, mixed thoroughly, and pre-warmed to 37°C before use. Because pancreatin activity degrades over time and varies between lots, laboratories should verify enzyme quality and avoid prolonged storage of the prepared medium.
Apparatus Configuration
A validated disintegration tester is fitted with a basket-rack assembly consisting of six open-ended glass tubes (approximately 77.5 mm long, 21.5 mm internal diameter) held vertically in a rack. The lower end of each tube is closed by a stainless-steel wire mesh screen. The assembly moves vertically through the medium at 30–32 cycles per minute; at the highest position, the mesh remains at least 15 mm below the liquid surface, and at the lowest position, it remains at least 25 mm above the vessel bottom. Guided perforated discs are added where the monograph directs their use.
Test Procedure
Place one dosage unit in each of the six tubes and operate the apparatus in dilute hydrochloric acid at 37°C for 2 hours. At the end of the acid stage, inspect each unit: none may disintegrate, and none may show cracking or softening of the coating. Withdraw the basket, wash the units gently with water to remove residual acid, replace the medium with pre-warmed artificial intestinal fluid, and continue operation for up to 60 minutes or the time specified in the monograph. Observe the units continuously or at defined intervals and record the time at which each unit disintegrates completely.
Acceptance Criteria and Judgment
The sample passes if all six units disintegrate completely within the specified time in artificial intestinal fluid. If exactly one of the six units fails to disintegrate or shows a firm core, six additional units from the same batch are tested, and all six retested units must disintegrate completely for the batch to comply. Any residue must be limited to insoluble coating or shell fragments lacking a firm, palpable core. Results are documented with timestamps, medium lot information, temperature records, and observations of the acid-stage integrity check.
Applications
Disintegration testing in artificial intestinal fluid is applied across the entire product lifecycle of delayed-release dosage forms:
- Batch release quality control: routine verification that commercial batches of enteric-coated tablets, capsules, and pellets meet pharmacopoeial disintegration specifications before release
- Formulation and process development: screening of enteric polymer grades, plasticizer levels, coating weight gain, curing conditions, and spray parameters to achieve robust acid resistance and rapid intestinal disintegration
- Stability studies: evaluation of disintegration performance after accelerated and long-term storage in the proposed packaging configuration, detecting coating brittleness, moisture-induced sticking, or cross-linking of gelatin shells
- Generic development and consistency evaluation: comparative testing against the reference listed product to support bioequivalence-driven formulation matching and post-approval change assessments
- Regulatory support: generation of specification data for registration dossiers, method validation documentation, and justification of acceptance limits
- Troubleshooting and failure investigation: root-cause analysis of delayed or incomplete disintegration, including assessment of coating uniformity, acid-stage pH drift, seal integrity of capsules, and enzyme activity of the test medium
- Advanced delivery research: performance testing of enzyme-triggered systems, pH-gradient systems, and polysaccharide-based colon-targeting platforms
FAQ
What is the difference between artificial intestinal fluid and pH 6.8 phosphate buffer?
Artificial intestinal fluid is a pH 6.8 phosphate buffer to which pancreatin has been added, providing amylase, protease, and lipase activity that simulates intestinal digestion. Plain pH 6.8 phosphate buffer contains no enzymes. Some monographs specify the buffer alone for the disintegration test, while pancreatin-containing artificial intestinal fluid is required where enzymatic interaction with the dosage form is relevant. Always follow the medium specified in the individual monograph.
Why must enteric-coated products first pass the acid stage before testing in artificial intestinal fluid?
The acid stage demonstrates that the enteric coating protects the drug from premature release in the stomach. A unit that cracks, softens, or disintegrates in dilute hydrochloric acid fails the test regardless of its subsequent performance in intestinal medium, because gastric exposure would release the active ingredient at the wrong anatomical site.
What is the standard disintegration time limit in artificial intestinal fluid?
For enteric-coated tablets and capsules, the compendial limit is complete disintegration within 60 minutes in pH 6.8 phosphate buffer or artificial intestinal fluid. Individual monographs may specify shorter limits or, for colon-targeted products, additional stages in higher-pH media.
What happens if one of the six units fails to disintegrate?
If no more than one of the six initial units fails, a retest is performed on six additional units from the same sample. The batch complies only if all six retested units disintegrate completely within the specified time. Failure of two or more initial units constitutes an outright failure.
Why is pancreatin added to the medium, and can it affect results?
Pancreatin replicates the enzymatic conditions of the small intestine and can interact with gelatin capsule shells, protein-based excipients, and certain polymeric coatings. Because enzyme activity varies between lots and declines during storage, the medium should be freshly prepared, and pancreatin of verified activity should be used to avoid false results.
Can disintegration testing replace dissolution testing?
No. Disintegration testing confirms that the dosage form breaks apart into small fragments, which is a prerequisite for dissolution, but it does not quantify the rate or extent of drug release. Dissolution profile testing remains the definitive method for characterizing drug release from delayed-release products and is required for bioequivalence and stability assessments.
What precautions ensure reliable results?
Maintain the bath at 37 ± 1°C without fluctuation, verify the stroke rate and amplitude of the apparatus during calibration, pre-warm the medium, remove residual acid from units before the buffer stage, and inspect the basket mesh regularly for blockage or damage that could impede disintegration or obscure the endpoint.
